<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01700946</url>
  </required_header>
  <id_info>
    <org_study_id>ALLR18</org_study_id>
    <secondary_id>NCI-2012-00587</secondary_id>
    <nct_id>NCT01700946</nct_id>
  </id_info>
  <brief_title>Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma</brief_title>
  <official_title>A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cookies for Kids' Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Assisi Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this protocol is to improve the cure rate of relapsed precursor&#xD;
      B-cell acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma.&#xD;
&#xD;
      This phase II trial is studying risk-directed therapy for B-lymphoblastic leukemia or&#xD;
      lymphoma in first relapse. Standard risk (SR) and high risk (HR) participants will receive&#xD;
      different therapy. Treatment will consist of chemotherapy for SR participants, and&#xD;
      chemotherapy followed by hematopoietic stem cell transplant (HSCT) for HR in first relapse.&#xD;
      Induction therapy consists of three blocks of chemotherapy. The first block is a novel&#xD;
      immunotherapy regimen that includes chemotherapy, rituximab and infusion of haploidentical&#xD;
      natural killer (NK) cells. SR participants will continue to receive chemotherapy for a total&#xD;
      duration of approximately 2 years. HR participants will be candidates for HSCT and will&#xD;
      proceed to transplant once a suitable donor is found and their minimal residual disease (MRD)&#xD;
      is negative.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective&#xD;
&#xD;
        -  To estimate the 3-year survival rate of participants with first relapse or primary&#xD;
           refractory precursor B-cell ALL and lymphoblastic lymphoma treated with risk-directed&#xD;
           therapy.&#xD;
&#xD;
      Secondary objectives&#xD;
&#xD;
        -  To determine minimal residual disease (MRD) levels at the end of remission induction&#xD;
           therapy for participants with relapsed precursor B-cell ALL and compare the results with&#xD;
           those in protocol ALLR17&#xD;
&#xD;
        -  To estimate levels of CD20 expression at baseline, during treatment with&#xD;
           dexamethasone-containing chemotherapy and following rituximab treatment in Block 1 of&#xD;
           remission induction therapy for relapsed precursor B-cell ALL.&#xD;
&#xD;
      STUDY DESCRIPTION:&#xD;
&#xD;
      The general treatment plan will consist of chemotherapy for standard-risk participants and&#xD;
      chemotherapy followed by HSCT for high risk participants in first relapse of B-precursor ALL&#xD;
      or lymphoblastic lymphoma. Remission induction for all participants consists of three blocks&#xD;
      of therapy, wherein the first block is a novel immunotherapy regimen that includes cytotoxic&#xD;
      chemotherapy, rituximab and infusion of haploidentical natural killer (NK) cells.&#xD;
      Standard-risk patients will continue to receive chemotherapy for a total duration of&#xD;
      approximately 2 years. High-risk patients will be candidates for HSCT and will proceed to&#xD;
      transplant once a suitable donor is found and the patient achieves negative MRD.&#xD;
&#xD;
      Participants will be assigned to the standard arm if they experience late relapse (&gt; or = 6&#xD;
      months after completion of frontline therapy) AND maximum residual disease (MRD) is &lt;0.01% at&#xD;
      the end of Block II of remission induction therapy. Provisional standard risk participants&#xD;
      (i.e., late relapse) will be re-assigned to high risk if MRD is &gt; or = 0.01% at the end of&#xD;
      Block II. Participants with lymphoma must be in complete remission at the end of Block III.&#xD;
&#xD;
      High risk participants will meet one of the following criteria:&#xD;
&#xD;
        -  Early relapse (on therapy or &lt;6 months after completion of frontline therapy), OR&#xD;
&#xD;
        -  Any relapse after hematopoietic stem cell transplant, OR&#xD;
&#xD;
        -  MRD &gt; or = 0.01% at the end of Block II of remission induction therapy, OR&#xD;
&#xD;
        -  Re-emergence of MRD at any time after attaining negative MRD on this clinical trial.&#xD;
&#xD;
      Natural killer (NK) cell collection: Donors who meet eligibility criteria will undergo&#xD;
      apheresis once. The cells obtained will be purified for CD56+ cells utilizing the CliniMACS&#xD;
      selection system. The NK cell product will undergo quality control testing following standard&#xD;
      operating procedures of the St. Jude Human Applications Laboratory.&#xD;
&#xD;
      OUTLINE (STANDARD RISK):&#xD;
&#xD;
      REMISSION INDUCTION:&#xD;
&#xD;
      BLOCK I: Patients receive dexamethasone orally (PO) or intravenously (IV) thrice daily (TID)&#xD;
      on days 1-8 and 21-28; vincristine sulfate IV on days 1, 21, 28, and 35; rituximab IV on days&#xD;
      4, 13, 20, and 27; clofarabine, cyclophosphamide, and etoposide IV on days 6-10; aldesleukin&#xD;
      subcutaneously (SC) once every other day (QOD) on days 11-19; and pegaspargase IV on days 21&#xD;
      and 35. Patients also undergo natural killer (NK) cell infusion on day 12. Patients may&#xD;
      receive triple intrathecal therapy comprising methotrexate, therapeutic hydrocortisone, and&#xD;
      cytarabine on days 1, 5, 8, 11, 21, and 28. Patients continue on to Block II after count&#xD;
      recovery.&#xD;
&#xD;
      BLOCK II: Patients receive methotrexate IV over 24 hours on days 1 and 8 and mercaptopurine&#xD;
      PO on days 1-21. Patients also receive triple intrathecal therapy on day 1. High-risk&#xD;
      patients with negative MRD continue on to transplantation. All patients with positive MRD&#xD;
      continue on to Block III after count recovery.&#xD;
&#xD;
      BLOCK III: Patients receive cytarabine IV over 2 hours twice daily (BID) on days 1-4 and&#xD;
      mitoxantrone hydrochloride IV over 1 hour on days 3-5. Patients also receive triple&#xD;
      intrathecal therapy on day 7.&#xD;
&#xD;
      INTERIM CONTINUATION (for patients unable to tolerate dose intensive chemotherapy): Patients&#xD;
      receive etoposide and cyclophosphamide IV on day 1, methotrexate IV on day 8, mercaptopurine&#xD;
      PO on days 8-14, teniposide and cytarabine IV on day 15, dexamethasone PO TID on days 22-26,&#xD;
      and vinblastine IV on day 22.&#xD;
&#xD;
      RE-INDUCTION THERAPY: Patients receive clofarabine, cyclophosphamide, and etoposide IV on&#xD;
      days 1-5; dexamethasone PO on days 1-6; and pegaspargase on days 6 and 20 and vincristine&#xD;
      sulfate IV on days 6, 13, and 20. Patients may also receive triple intrathecal therapy on&#xD;
      days 1 and 15. Patients continue on to continuation treatment after count recovery.&#xD;
&#xD;
      CONTINUATION TREATMENT: Patients receive methotrexate IV over 2 hours on day 1 and&#xD;
      mercaptopurine PO on days 1-7 of weeks 1, 2, 5, and 6; teniposide and cytarabine IV on day 1&#xD;
      of weeks 3 and 7; vincristine sulfate IV on day 1 of week 4; dexamethasone PO TID on days 1-5&#xD;
      of weeks 4 and 8; and vinblastine IV on day 1 of week 8. Treatment repeats every 8 weeks for&#xD;
      up to 10 courses in the absence of disease progression or unacceptable toxicity. Patients may&#xD;
      also receive triple intrathecal therapy on day 1 of week 1 of all courses and day 1 of week&#xD;
      5, courses 1-5.&#xD;
&#xD;
      Due to the unavailability of the drug Teniposide (VM-26), etoposide (VP-16) will be&#xD;
      substituted for the remaining doses for patients currently on this study. The protocol&#xD;
      Section 5.1.3 allows this substitution.&#xD;
&#xD;
      OUTLINE: GROUP 2 (high risk defined as participants not meeting the standard risk criteria&#xD;
      noted above):&#xD;
&#xD;
      Patients receive Remission Induction (Blocks I, II, and III) treatment as described above for&#xD;
      Group 1. Patients then undergo allogeneic hematopoietic stem cell transplantation (HSCT) as&#xD;
      soon as they have negative MRD. Patients with negative MRD may continue chemotherapy until a&#xD;
      suitable donor is found.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 4 months for 1 year,&#xD;
      every 6 months for 1 year, and then yearly for up to 10 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2013</start_date>
  <completion_date type="Actual">July 24, 2021</completion_date>
  <primary_completion_date type="Actual">July 24, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year overall survival rate of patients with relapsed ALL</measure>
    <time_frame>At 3 years of follow-up since the on-study date of the last enrolled patient</time_frame>
    <description>Estimate the 3-year survival rate of participants with first relapse or primary refractory precursor B-cell ALL treated with risk-directed therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3-year event-free survival rates in patients with relapsed ALL</measure>
    <time_frame>At 3 years of follow-up since the on-study date of the last enrolled patient</time_frame>
    <description>Estimate the 3-year event-free survival rate of participants with first relapse or primary refractory precursor B-cell ALL treated with risk-directed therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with positive minimal residual disease</measure>
    <time_frame>At 3 months after the on-study date of the last enrolled patient</time_frame>
    <description>To determine minimal residual disease (MRD) levels at the end of remission induction therapy for participants with relapsed precursor B-cell ALL and compare the results with those in protocol ALLR17.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of CD20 expression levels</measure>
    <time_frame>approximately 5 weeks after the on-study date of the last enrolled patient</time_frame>
    <description>To estimate mean levels of CD20 expression at baseline, during treatment with dexamethasone-containing chemotherapy and following rituximab treatment in Block 1 of remission induction therapy for relapsed precursor B-cell ALL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median CD20 expression levels</measure>
    <time_frame>approximately 5 weeks after the on-study date of the last enrolled patient</time_frame>
    <description>To estimate median levels of CD20 expression at baseline, during treatment with dexamethasone-containing chemotherapy and following rituximab treatment in Block 1 of remission induction therapy for relapsed precursor B-cell ALL.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Childhood B-Lymphoblastic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Standard Risk</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interventions: dexamethasone, vincristine sulfate, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, teniposide, vinblastine, natural killer cell infusion, laboratory biomarker analysis, therapeutic hydrocortisone&#xD;
Cells for infusion are prepared using the CliniMACS System.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interventions: dexamethasone, vincristine, rituximab, clofarabine, cyclophosphamide, etoposide, aldesleukin, pegaspargase, methotrexate, mercaptopurine, cytarabine, mitoxantrone, natural killer cell infusion, allogeneic hematopoietic stem cell transplantation, laboratory biomarker analysis, therapeutic hydrocortisone&#xD;
Cells for infusion are prepared using the CliniMACS System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>given intravenously or orally</description>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_label>Standard Risk</arm_group_label>
    <other_name>Decadron(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>given intravenously</description>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_label>Standard Risk</arm_group_label>
    <other_name>Oncovin(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>given intravenously</description>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_label>Standard Risk</arm_group_label>
    <other_name>Rituxan(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clofarabine</intervention_name>
    <description>given intravenously</description>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_label>Standard Risk</arm_group_label>
    <other_name>Clolar(TM)</other_name>
    <other_name>clofarex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>given intravenously</description>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_label>Standard Risk</arm_group_label>
    <other_name>Cytoxan(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>given intravenously</description>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_label>Standard Risk</arm_group_label>
    <other_name>VP-16</other_name>
    <other_name>Vepesid(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
    <description>given subcutaneously</description>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_label>Standard Risk</arm_group_label>
    <other_name>IL-2</other_name>
    <other_name>interleukin-2</other_name>
    <other_name>Proleukin (R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegaspargase</intervention_name>
    <description>given intravenously</description>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_label>Standard Risk</arm_group_label>
    <other_name>PEG-ASP</other_name>
    <other_name>Peg-L-asparaginase</other_name>
    <other_name>PEG-asparaginase</other_name>
    <other_name>Oncaspar(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>given intrathecally or intravenously</description>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_label>Standard Risk</arm_group_label>
    <other_name>MTX</other_name>
    <other_name>HDMTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mercaptopurine</intervention_name>
    <description>given orally</description>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_label>Standard Risk</arm_group_label>
    <other_name>6-MP</other_name>
    <other_name>Purinethol(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>given intrathecally or intravenously</description>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_label>Standard Risk</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar-U(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone</intervention_name>
    <description>given intravenously</description>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_label>Standard Risk</arm_group_label>
    <other_name>Novantrone(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teniposide</intervention_name>
    <description>given intravenously</description>
    <arm_group_label>Standard Risk</arm_group_label>
    <other_name>VM-26</other_name>
    <other_name>Vumon(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine</intervention_name>
    <description>given intravenously</description>
    <arm_group_label>Standard Risk</arm_group_label>
    <other_name>Velban(R)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>natural killer cell infusion</intervention_name>
    <description>undergo allogeneic natural killer cell infusion</description>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_label>Standard Risk</arm_group_label>
    <other_name>NK cell infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>correlative studies</description>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_label>Standard Risk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>therapeutic hydrocortisone</intervention_name>
    <description>given intrathecally</description>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_label>Standard Risk</arm_group_label>
    <other_name>Cortef</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic hematopoietic stem cell transplantation</intervention_name>
    <description>undergo allogeneic HSCT</description>
    <arm_group_label>High Risk</arm_group_label>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CliniMACS</intervention_name>
    <description>The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.</description>
    <arm_group_label>High Risk</arm_group_label>
    <arm_group_label>Standard Risk</arm_group_label>
    <other_name>Cell Selection System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Must have relapsed or refractory precursor B-cell acute lymphoblastic leukemia or&#xD;
             acute lymphoblastic lymphoma.&#xD;
&#xD;
          -  Participants with leukemia must meet one of the following:&#xD;
&#xD;
               1. In first hematologic relapse, defined as the reappearance (in a patient who has&#xD;
                  previously achieved remission) of leukemia blasts in the bone marrow or&#xD;
                  peripheral blood, OR&#xD;
&#xD;
               2. Refractory to one or two courses of frontline induction therapy (≥ 5% blasts in&#xD;
                  the bone marrow or peripheral blood confirmed by flow cytometric analysis).&#xD;
&#xD;
          -  Participant with lymphoma must meet one of the following:&#xD;
&#xD;
               1. In first relapse, OR&#xD;
&#xD;
               2. Refractory to one or two courses of frontline induction therapy with measurable&#xD;
                  disease&#xD;
&#xD;
                    -  Should flow cytometric analyses suggest relapse (by the reappearance of a&#xD;
                       similar immunophenotype to the original leukemia) in the presence of &lt;5%&#xD;
                       blasts morphologically, a repeat bone marrow test is recommended to confirm&#xD;
                       relapse.&#xD;
&#xD;
                    -  Molecular or genetic relapse is characterized by the reappearance of a&#xD;
                       cytogenetic or molecular abnormality.&#xD;
&#xD;
                    -  Early relapse is defined as relapse on therapy or &lt; 6 months after&#xD;
                       completion of frontline therapy. Late relapse is defined as relapse&#xD;
                       occurring ≥ 6 months after completion of frontline therapy.&#xD;
&#xD;
          -  Participant's age is &lt; 22 years at time of enrollment (e.g. participant is eligible&#xD;
             until 22nd birthday).&#xD;
&#xD;
          -  Prior therapy:&#xD;
&#xD;
               1. There is no waiting period for participants who relapse while receiving frontline&#xD;
                  therapy and are free from side effects attributable to such therapy.&#xD;
&#xD;
               2. Emergent radiation therapy, one dose of intrathecal chemotherapy, and up to 7&#xD;
                  days of steroids for treatment of relapse are permitted before start of treatment&#xD;
                  in participants who relapse after completion of frontline therapy.&#xD;
&#xD;
               3. At least 90 days have elapsed since bone marrow transplant and participant is off&#xD;
                  immune suppression for a minimum of 2 weeks, if applicable. Participants with ALL&#xD;
                  or NHL who were transplanted in first remission are eligible for this study.&#xD;
&#xD;
        Organ function requirements&#xD;
&#xD;
          -  Hepatic: Total bilirubin ≤ upper limit of normal (ULN) for age, or if total bilirubin&#xD;
             is &gt; ULN, direct bilirubin ≤ 1.4 mg/dl&#xD;
&#xD;
          -  Cardiac: Shortening fraction ≥ 28%&#xD;
&#xD;
          -  Renal: Glomerular filtration rate &gt;50cc/min/1.73 m^2, OR maximum serum creatinine (SC)&#xD;
             based on age as follows:&#xD;
&#xD;
               -  If age is 1 to 2 years, then maximum SC is 0.6 mg/dL&#xD;
&#xD;
               -  If age is 2 to 6 years, then maximum SC is 0.8 mg/dL&#xD;
&#xD;
               -  If age is 6 to 10 years, then maximum SC is 1 mg/dL&#xD;
&#xD;
               -  If age is 10 to &lt;13 years, then maximum SC is 1.2 mg/dL&#xD;
&#xD;
               -  If age is 13 to 16 years, then maximum SC is 1.5 mg/dL for males and 1.4 mg/dL&#xD;
                  for females&#xD;
&#xD;
               -  If age is &gt;16 years, then maximum SC is 1.7 mg/dL for males and 1.4 mg/dL for&#xD;
                  females&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Leukemia participants ages 1 to 5 years with induction failure AND favorable&#xD;
             cytogenetics (i.e., hyperdiploidy defined as DNA index ≥1.16 or modal chromosome&#xD;
             number ≥51, or ETV6-RUNXI).&#xD;
&#xD;
          -  Hepatitis B or HIV infection.&#xD;
&#xD;
          -  Pregnant or breast-feeding&#xD;
&#xD;
          -  Inability or unwillingness or research participant or legal guardian/representative to&#xD;
             give written informed consent.&#xD;
&#xD;
        INCLUSION CRITERIA FOR NK CELL DONORS:&#xD;
&#xD;
          -  Donor is at least 18 years of age.&#xD;
&#xD;
          -  Donor is a family member.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sima Jeha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rady Children's Hospital and Health Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <link>
    <url>http://www.stjude.org/protocols</url>
    <description>Clinical Trials Open at St. Jude</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 1, 2012</study_first_submitted>
  <study_first_submitted_qc>October 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2012</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>leukemia</keyword>
  <keyword>lymphoma</keyword>
  <keyword>Non-Hodgkins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone hemisuccinate</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Clofarabine</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Teniposide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

